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Impact of allergic rhinitis on asthma: effects on
bronchodilation testing
Giorgio Ciprandi, MD*; Ignazio Cirillo, MD†; Angela Pistorio, MD‡; Stefania La Grutta, MD§;
and Mariangela Tosca, MD¶
Background: A remarkable relationship exists between the upper and lower airways. Bronchial obstruction is a paramount
feature of asthma, and its reversibility is considered a main step in asthma diagnosis.
Objective: To investigate the degree of bronchodilation and possible risk factors related to it in patients with moderate-severe
persistent allergic rhinitis alone.
Methods: A total of 375 patients with moderate-severe persistent allergic rhinitis and 115 controls were prospectively and
consecutively evaluated by means of clinical examination, skin prick testing, spirometry, and bronchodilation testing.
Results: Patients with rhinitis showed a significant increase in forced expiratory volume in 1 second (FEV
1
) after bronchodi-
lation testing compared with basal values and levels in controls (P  .001). Two-thirds of the rhinitic patients had reversibility
(12% basal levels). Patients with reversibility had lower FEV1 levels, longer rhinitis duration, and mite and tree allergies.
Conclusions: This study highlights the close link between the upper and lower airways and the relevance of performing
bronchodilation testing in patients with moderate-severe persistent allergic rhinitis.
Ann Allergy Asthma Immunol. 2008;101:42–46.
INTRODUCTION
Allergic rhinitis is characterized by typical symptoms, includ-
ing nasal itching, sneezing, rhinorrhea, and obstruction, in-
duced by an IgE-mediated inflammatory response of the nose
to allergen exposure. Indeed, inflammation may be consid-
ered a condicio sine qua non of allergic rhinitis.1 Infiltration
by inflammatory cells, including T cells, mast cells, and
eosinophils, characterizes allergic inflammation.2 The cyto-
kine pattern is typically characterized by a TH2 polarization.3
The TH2-derived cytokines account for recruiting and acti-
vating eosinophils in the airways: actually, eosinophil infil-
tration may be considered a reliable marker of allergic in-
flammation.4
On the other hand, asthma is defined as chronic inflamma-
tion of the lower airways.5 The allergic airway inflammation
may, therefore, induce airflow limitation at the nasal and
bronchial levels.6 A close link between allergic rhinitis and
asthma has been widely reported.7,8 Furthermore, allergic
rhinitis has been demonstrated to be a strong risk factor for
the onset of asthma in adults.9
From a pathophysiologic point of view, asthma is charac-
terized by airflow obstruction.10,11 Bronchial airflow may be
easily evaluated by means of spirometry. Several spirometric
variables may be considered, but the gold standard for de-
tecting asthma is forced expiratory volume in 1 second
(FEV1) according to Global Initiative for Asthma guidelines.5
In addition, reversibility of airflow obstruction is considered
a characteristic of asthma. This reversibility may be sponta-
neous or induced by drugs such as bronchodilators. To eval-
uate reversibility, the bronchodilation test is commonly per-
formed in a clinical setting.
Because allergic rhinitis may frequently be associated with
or precede asthma, the World Health Organization document
Allergic Rhinitis and Its Impact on Asthma6 clearly under-
lines the role of allergic rhinitis as a risk factor for asthma and
suggests considering bronchial involvement in patients with
allergic rhinitis. Concerning this issue, it has been demon-
strated that FEV1 may be impaired in approximately 5% of
patients with allergic rhinitis who perceive nasal symptoms
alone.12 Furthermore, slight spirometric impairment, such as
reduced forced expiratory flow between 25% and 75% val-
ues, may frequently be found in rhinitic patients, and it might
be a reliable marker of early bronchial involvement.13 There-
fore, allergic rhinitis may be considered the first step in a
progression of respiratory allergy toward asthma. Further-
more, the Allergic Rhinitis and Its Impact on Asthma docu-
ment revised the classification of allergic rhinitis, defining 2
types: intermittent and persistent. The new classification does
not consider the type of allergen but the duration (days per
week and consecutive weeks) and the severity of symptoms
(mild or moderate-severe).
Nevertheless, the possible presence of spirometric abnor-
malities in patients with allergic rhinitis has been well doc-
umented; however, no studies, to our knowledge, have been
conducted in patients with moderate-severe persistent allergic
rhinitis about the degree of reversibility to bronchodilation
testing. Therefore, a large group of patients with moderate-
severe persistent allergic rhinitis alone were evaluated to
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investigate the degree of bronchodilation and possible risk
factors related to it.
MATERIALS AND METHODS
Study Design and Participants
The study included 375 patients with moderate-severe per-
sistent allergic rhinitis who were prospectively and consecu-
tively evaluated using clinical examination, skin prick testing,
spirometry, and bronchodilation testing. A total of 115 indi-
viduals were enrolled as controls. Patient characteristics, in-
cluding sex, age, and duration of rhinitis, are reported in
Table 1. All the patients were Navy sailors who had been
referred to a Navy hospital for a mandatory periodic visit for
maintaining the qualification; therefore, this study is exempt
from institutional review board review. Informed consent was
obtained from each participant.
A detailed clinical history was taken, and a complete
physical examination was performed. Patients were included
in the study on the basis of a clinical history of persistent
allergic rhinitis and the presence of moderate-severe nasal
symptoms according to validated criteria.6 The exclusion
criteria were as follows: any history of asthma or the presence
of asthma symptoms, including cough, wheezing, dyspnea,
and shortness of breathing; acute or chronic upper respiratory
tract infections; anatomical nasal disorders (nasal polyps,
septum deviation); previous or current smoking (screened by
expired carbon dioxide evaluation); previous or current spe-
cific immunotherapy; and use of nasal or oral corticosteroids,
nasal or oral vasoconstrictors, antileukotrienes, and antihis-
tamines during the previous 4 weeks (if they assumed phar-
macologic treatment, they were asked to return after stopping
the medication use for 4 weeks). All the patients were treated
on demand only with drugs alone. The diagnosis of persistent
allergic rhinitis was made on the basis of a history of nasal
symptoms and positive skin prick test results according to
validated criteria.6
Testing
Skin prick testing was performed as stated by the European
Academy of Allergy and Clinical Immunology.14 The panel
consisted of house dust mites (Dermatophagoides farinae and
Dermatophagoides pteronyssinus), cat, dog, grass mix, Com-
positae mix, Parietaria officinalis, birch, hazel, olive tree,
Alternaria tenuis, Cladosporium, and Aspergilli mix (Stall-
ergenes, Milan, Italy). Spirometry was performed using a
computer-assisted spirometer (Pulmolab 435-Spiro 235; Mor-
gan Medical, Rainham, England) and according to interna-
tional guidelines.5,10,11 Briefly, 3 blows (every 5 minutes)
were performed, and the best result was considered. Test of
bronchodilation was performed according to international
guidelines and using a salbutamol metered dose of 400 g.
Reversibility was considered if an increase of at least 12% in
FEV1 from baseline was achieved, according to international
guidelines.10,11
Statistical Analysis
Descriptive statistical analyses were performed, and quanti-
tative variables are reported as mean (SD) or as median
(range) in the case of skewed distribution. Qualitative data
are reported as frequency (percentage). Qualitative data were
compared among various groups of patients using the 2 test
or the Fisher exact test in the case of expected frequencies
less than 5. Quantitative normally distributed data were com-
pared between 2 groups of patients using the t test; when the
homoscedasticity assumption was not fulfilled, the Mann-
Whitney test was used as a nonparametric counterpart (eg,
age of the patients). Quantitative variables were compared
among the 3 groups (such as patients with persistent allergic
rhinitis and reversibility, patients with persistent allergic rhi-
nitis without reversibility, and control subjects) by means of
analysis of variance or the nonparametric Kruskal-Wallis test;
post hoc comparisons were performed using the Scheffe´ test
or the nonparametric Dunn test.
Quantitative variables (eg, FEV1 % of predicted) for paired
data (pretest and posttest values) were compared using the
Wilcoxon test. All tests were 2 sided, and P  .05 was
considered statistically significant. A statistical software pro-
gram (Statistica release 6; StatSoft Corp, Tulsa, Oklahoma)
was used for all the analyses.
RESULTS
Three hundred seventy-five patients (298 men and 77
women) and 115 control subjects (102 men and 13 women)
were included in the study. The mean (SD) age of patients
was 23.9 (3.9) years and of controls was 22.6 (2.4) years
(Mann-Whitney test, P  .31). Two hundred fifty-four pa-
tients had a diagnosis of allergic rhinitis, and 121 had a
diagnosis of allergic rhinoconjunctivitis. All of the included
individuals have clinically relevant sensitization to at least 1
allergen to which they were exposed at the time of testing.
Patients had a median rhinitis duration of 3 years, and none
had FEV1 values less than 80% of predicted (Table 1). Thus,
patients were studied on the basis of their response to bron-
chodilation testing. Figure 1A shows pretest and posttest
FEV1 values in patients and controls. Mean pretest FEV1
values are approximately 90% of predicted (mean [SD],
89.8% [6.1%] of predicted; median, 90.0% of predicted) and
reach a mean (SD) posttest value of 100.8% (5.2%) of pre-
dicted (median, 102.0% of predicted). This increase is statis-
Table 1. Characteristics of the 375 Study Patients
Characteristic Value
Female sex, No. (%) 77 (20.5)
Age, median (range), y 24 (18–48)
Rhinitis duration, median (range), y 3 (1–12)
Pretest FEV1, median (range), % of predicted 90 (80–109)
Pretest FVC, median (range), % of predicted 102 (77–116)
Pretest FEF25–75, median (range), % of predicted 72 (56–79)
Abbreviations: FEF25–75, forced expiratory flow between 25% and
75%; FEV1, forced expiratory volume in 1 second; FVC, forced vital
capacity.
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tically significant (Wilcoxon test, P  .001). In addition,
pretest and posttest FEV1 values are higher in controls than in
patients; pretest and posttest values in controls also show a
significant increase (pretest FEV1 values: mean [SD], 105.6%
[8.2%] of predicted; median, 105% of predicted; and posttest
FEV1 values: mean [SD], 109.4% [10.1%] of predicted; me-
dian, 112% of predicted) (Wilcoxon test, P .001) (Fig 1A).
Furthermore, posttest FEV1 values remain significantly lower
in patients than in controls (Mann-Whitney test, P  .001).
The percentage change () in FEV1 values (with respect to
pretest values) is significantly higher in patients vs controls
(Mann-Whitney test, P .001) (Fig 1B). Of the 375 patients,
251 (66.9%) showed a percentage increase in FEV1 of 12% or
greater and, therefore, had reversibility, whereas 124 (33.1%)
showed a percentage increase in FEV1 of less than 12%. None
of the controls was “reversible”; in fact, all the percentage
increases in FEV1 in the control group were less than 12%.
Mean FEV1 values at baseline in the 3 participant groups
are shown in Figure 2A. Patients with a  FEV1 % of
predicted of 12% or greater have lower levels of pretest FEV1
vs patients with a  FEV1 of less than 12% or controls (Dunn
test, P  .01 for both). As shown in Figure 2B, rhinitis
duration is significantly higher in patients with a  FEV1 of
12% or greater compared with patients with a  FEV1 of less
than 12%.
Allergen sensitization in the 2 groups of patients ( FEV1
12% vs  FEV1 12%) is given in Table 2. Patients with
Figure 1. A, Pretest and posttest forced expiratory volume in 1 second
(FEV1) values in patients (striped boxes) and controls (white boxes).
****P  .001. B, Percentage change in FEV1 values is significantly higher
in patients vs controls. Error bars represent SD.
Figure 2. A, Pretest forced expiratory volume in 1 second (FEV1) values
in the 3 groups: patients with a percentage change () in FEV1 % of
predicted of 12% or greater, patients with a  FEV1 of less than 12%, and
controls (all with a  FEV1 of 12%). B, Rhinitis duration is significantly
higher in patients with a  FEV1 % of predicted of 12% or greater.
44 ANNALS OF ALLERGY, ASTHMA & IMMUNOLOGY
 FEV1 of 12% or greater are more frequently positive to
house dust mites and trees and are less frequently positive to
molds.
DISCUSSION
Allergic rhinitis and asthma may be considered as a single
syndrome involving 2 parts of the respiratory tract, as docu-
mented by 2 elegant experimental studies.15,16 Patients with
allergic rhinitis may frequently present with asthma symp-
toms or spirometric impairment. Indeed, impaired FEV1 val-
ues may be detected in some patients with allergic rhinitis
who also perceive nasal symptoms alone.12 Thus, this finding
underlines the link between the upper and lower airways and
underlines the concept that allergic rhinitis usually precedes
overt asthma.
Asthma is characterized by airflow obstruction that is
typically reversible, spontaneously or pharmacologically. The
demonstration of bronchial reversibility is a main step in the
diagnosis of asthma and is performed by bronchodilation
testing. Bronchodilation testing should be considered as an
integral part of spirometry because it is easy to perform and
may provide interesting suggestions also in patients without
overt bronchial airflow obstruction.
The present study investigated the response to the bron-
chodilation test in a large cohort of patients with moderate-
severe persistent allergic rhinitis alone, ie, perceiving only
nasal symptoms. Several interesting findings have been ob-
served in this study. First, it provides evidence that a large
percentage (approximately two-thirds) of patients with mod-
erate-severe persistent allergic rhinitis show reversibility to
bronchodilation testing (ie, an increase greater than 12% in
basal FEV1 values). Note that all the patients had normal
basal FEV1 values (ie, 80% of predicted or greater). Further-
more, bronchodilation has been observed also in patients
without reversibility (ie, less than a 12% increase in basal
FEV1 values), and the increase in FEV1 values is significantly
higher than in controls. Therefore, it is conceivable to for-
mulate the hypothesis that the response to bronchodilation
testing might be considered as further proof of bronchial
impairment in allergic rhinitis.
Second, the response degree to bronchodilation testing
depends on basal FEV1 values. Indeed, patients with revers-
ibility had significantly lower FEV1 values than did patients
without reversibility. This issue underlines the concept that
reversibility to bronchodilation testing is associated with
early bronchial airflow limitation, although in the presence of
borderline FEV1 values.
Third, reversibility is associated with longer duration of
rhinitis. This finding confirms that of a previous study17
providing evidence that spirometric impairments are more
frequent in patients with long-lasting rhinitis. The duration of
allergic rhinitis constitutes an important factor that promotes
the development of bronchial involvement. The possible ex-
planation of this phenomenon might depend on the allergic
inflammation that persists across time and tends to progress
from the nose into the bronchi.6
Fourth, the reversibility is associated with specific sensiti-
zations (ie, to house dust mites and trees). This fact confirms
the previous outcome: mite allergy is characterized by the
well-known concept of minimal persistent inflammation.18
The continuous exposure to causal allergen induces persis-
tence of inflammation that may favor complications. In ad-
dition, it has been evidenced that birch allergy is also char-
acterized by this phenomenon.19 Therefore, as in asthmatic
patients also in rhinitic patients the response to bronchodila-
tion testing seems to depend on airway inflammation. The
implication of this study is that in addition to having upper
airway inflammation, these allergic rhinitic patients also have
lower airway inflammation, which may be contributing to
their lower FEV1 values and significant reversibility on spi-
rometry.
In conclusion, this study provides evidence that patients
with moderate-severe persistent allergic rhinitis may fre-
quently show reversibility to bronchodilation testing. This
event may account for early bronchial involvement as pa-
tients were perceiving nasal symptoms alone. The reversibil-
ity is also associated with lower basal FEV1 values, longer
duration of rhinitis, and sensitization to mites or trees. Thus,
it could be useful to perform bronchodilation testing in pa-
tients with these characteristics.
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Table 2. Allergen Sensitization in the 375 Study Patients Divided in 2 Groups According to Reversibility
Sensitization to
Percentage change in FEV1 % of predicted
P value (2 test)
>12% (n  251) <12% (n  124)
House dust mites, No. (%) 183 (72.9) 73 (58.9) .006
Trees, No. (%) 146 (58.2) 46 (37.1) .001
Parietaria, No. (%) 160 (63.7) 70 (56.5) .17
Grass, No. (%) 35 (13.9) 15 (12.1) .62
Molds, No. (%) 34 (13.5) 34 (27.4) .001
Dog or cat, No. (%) 17 (6.8) 9 (7.3) .86
Compositae, No. (%) 6 (2.4) 7 (5.6) .13
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